The emerging role of sST2 blocking in the therapy of graft-versus-host disease

Xiao, Yifan; Zheng, Fang

doi:10.21037/atm.2016.10.22

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two forms of ST2: transmembrane (mST2) and soluble isoforms (sST2) have been described ( Mueller and Jaffe, 2015 ). The sST2 has been identified as a biomarker for cardiac, pulmonary and graft-versus-host diseases ( Bajwa et al, 2015 ; Bayes-Genis et al, 2015 ; Xiao and Zheng, 2016 ). Recent studies have demonstrated a protective role of IL-33/ST2 in several inflammatory settings ( Miller et al, 2008 ; Mato et al, 2009 ; Milovanovic et al, 2012 ).…”

Section: Il-33: An Alarmin Cytokine That Regulates Innate Immunity and Inflammationmentioning

confidence: 99%

Targeting Regulatory T Cells for Therapy of Lupus Nephritis

et al. 2022

View full text Add to dashboard Cite

Lupus glomerulonephritis (LN) is a complex autoimmune disease characterized by circulating autoantibodies, immune-complex deposition, immune dysregulation and defects in regulatory T cell (Tregs). Treatment options rely on general immunosuppressants and steroids that have serious side effects. Approaches to target immune cells, such as B cells in particular, has had limited success and new approaches are being investigated. Defects in Tregs in the setting of autoimmunity is well known and Treg-replacement strategies are currently being explored. The aim of this minireview is to rekindle interest on Treg-targeting strategies. We discuss the existing evidences for Treg-enhancement strategies using key cytokines interleukin (IL)-2, IL-33 and IL-6 that have shown to provide remission in LN. We also discuss strategies for indirect Treg-modulation for protection from LN.

show abstract